Project Grant K23GM163057
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $192K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
West Hollywood, CA 90048, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Cedars-Sinai Medical Center $1.481 million on July 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate single-cell proteome heterogeneity arising from myosin heavy chain 7 (MYH7) mutations associated with hypertrophic cardiomyopathy and the recovery mechanisms induced by the therapeutic agent mavacamten. The research applies high-sensitivity mass spectrometry and single-cell proteomics to quantify over...
- The National Heart, Lung, and Blood Institute awarded Cedars-Sinai Medical Center $717,680 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate immune epithelial niche mechanisms underlying post-viral lung fibrosis. The research examines how anti-viral CD8+ T cell immunity, specifically interferon-gamma signaling and macrophage-derived interleukin-1 beta secretion, impairs alveolar epithelial repair following severe respiratory viral infections. The...
- Federal Project Grant Award Summary Award Overview: Cedars-Sinai Medical Center received a $419,321 Project Grant from the National Institute on Aging (CFDA 93.866 – Aging Research) to conduct a proof-of-concept research study examining neurocognitive dysfunction in patients with adrenal cortisol insufficiency (ACI). The award period runs from September 15, 2025, through August 31, 2027. Products and Services: The primary deliverable is a short-term research study that defines neurocognitive...
- The National Heart, Lung, and Blood Institute awarded Cedars-Sinai Medical Center $1.379 million on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cardioprotective mechanisms of Y RNA signaling in macrophages as a potential therapeutic approach to myocardial infarction. The research dissects how a small non-coding RNA called YREX3—secreted by therapeutically-enhanced cardiac stromal cells—signals macrophages to enhance their capacity for...
- Federal Project Grant Award Summary Cedars-Sinai Medical Center received a $974,043 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) with an award date of September 1, 2025, and a completion date of August 31, 2029. The award funds research titled "Early Cardiac Biomarkers of Inflammation and Remodeling in DMD" (Duchenne muscular dystrophy), to be conducted at the medical center's West Hollywood, California...
- Federal Project Grant Award Summary Cedars-Sinai Medical Center received a $2.59M project grant from the National Institute on Aging (Aging Research, CFDA 93.866) awarded September 15, 2025, for research examining hypothalamic pathways involved in age-related homeostatic dysregulation. The four-year project (completion date August 31, 2029) will investigate the role of supraoptic hypothalamic neurons in physiological decline with aging, with particular focus on how arginine-vasopressin (AVP)...
- The National Institute on Aging awarded $671,107 to Cedars-Sinai Medical Center on July 15, 2026, under the Aging Research program (CFDA 93.866) to investigate P53 acetylation as a driver of alveolar progenitor cell senescence in idiopathic pulmonary fibrosis. The recipient is conducting research into the mechanisms by which aberrant P53 activation, stabilized through acetylation and enhanced by increased CBP/P300 acetyltransferase activity and reduced SIRT1 expression, initiates and perpetuates...
- This Project Grant award, totaling $2,685,519.00, was made by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to Cedars-Sinai Medical Center in West Hollywood, CA. The grant supports advanced biomedical research to define human correlates of super-evasive disseminated tumor cells, assess their pathological relevance, and explore methods to eradicate them. This 4-year research project, running from July 1, 2025 to June 30, 2029, aims to...
- Federal Project Grant Award Summary Cedars-Sinai Medical Center received a $113,340 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective August 15, 2025 through August 14, 2028. The award supports research on ex vivo preservation techniques for vascularized composite allotransplantation (VCA) with a specific focus on developing tolerance induction protocols suitable for clinical application. This research...
- The National Institute of Neurological Disorders and Stroke awarded Cedars-Sinai Medical Center $1,289,919 on April 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate the mechanistic role of alpha-5 integrin in amyotrophic lateral sclerosis pathology. The project defines the cell type-specific contributions of alpha-5 integrin in ALS pathogenesis using conditional knockout models to selectively delete alpha-5...